Business
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2020 Financial Results
REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company
About this update from Soleno Therapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter and nine months ended September 30, 2020.\n Third Quarter 2020 and Recent Corporate Highlights Announced updated top-line results from Phase III DESTINY PWS (C601) study evaluating once-daily Diazoxide Choline Controlled-Release (DCCR) tablets for patients with Prader Willi Syndrome (PWS) º Significant DCCR exposure response relationship between DCCR plasma concentrations and change from baseline in hyperphagia supporting the therapeutic benefit of DCCR treatment on hyperphagia º Significant improvements in leptin and adiponectin, adipokines that are differentially expressed in obesity and cardiovascular diseases, deepening the company’s insight into the mechanism of action in PWS º Significant reductions in fat mass and a trend towards increased lean body mass were observed º Interim analysis of the change in HQ-CT from C601 baseline at week 13 of C602, the open-label extension study, indicated that nearly all subjects treated with DCCR showed improvement in hyperphagia, supporting the long-term clinical benefit of treatment with DCCR in PWS º More than 100 subjects continue to be treated with DCCR in C602, with 20 having been treated for more than a year º The safety profile of DCCR remains generally consistent with the known profile of diazoxide and prior experience with DCCR, with no serious unexpected adverse events related to DCCR reported º Soleno reaffirms plan to meet with the FDA before the end of this calendar quarter to determine next stepsBody composition data from C601 were highlighted in a late-breaking oral presentation at The Obesity Society’s ObesityWeek® 2020 meeting “We continue to be encouraged by the improvements in hyperphagia and other PWS associated behaviors, as well as positive body composition and metabolic data seen in the updated results from our Phase III program evaluating DCCR for PWS, a disease with life-threatening comorbidities,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. “We remain confident in the potential of DCCR to address the unmet need for a safe and eff...